Increased mortality rates seen in chronic Hep C patients with pre-cirrhotic advanced fibrosis

March 06, 2017

Researchers noted that the increase in mortality for patients treated with peginterferon did not emerge until three years into treatment and continued for several years after treatment ceased. The excess mortality in the treatment group was mainly linked to non-liver-related causes. ???No specific cause of death accounted for the excess mortality, but deaths were unrelated to direct effects of peginterferon treatment,??? concluded Dr. Di Bisceglie. Researchers could not identify an excess frequency of any single condition or disease category for cause of non-liver related deaths. Only one death was determined to be a probable result of complications from peginterferon therapy. ???Our findings suggest that the long-term use of peginterferon should be evaluated cautiously and that attention to unrelated complications is warranted.???

This study is published in Hepatology.

Full citation: ???Excess Mortality in Patients With Advanced Chronic Hepatitis C Treated with Long-Term Peginterferon.??? Adrian Di Bisceglie, Anne Stoddard, Jules Dienstag, Mitchell Shiffman, Leonard Seeff, Herbert L. Bonkovsky, Chihiro Morishima, Elizabeth Wright, Kristen Snow, William Lee, Robert Fontana, Timothy Morgan, and Marc Ghany for the Halt-C Trial Group. Hepatology; Published Online: January 11, 2011 (DOI:10.1002/hep.24169); Print Issue Date: April 2011. onlinelibrary.wiley/doi/10.1002/hep.24169/abstract

About the Journal Hepatology is the premier publication in the field of liver disease, publishing original, peer-reviewed articles concerning all aspects of liver structure, function and disease. Each month, the distinguished Editorial Board monitors and selects only the best articles on subjects such as immunology, chronic hepatitis, viral hepatitis, cirrhosis, genetic and metabolic liver diseases and their complications, liver cancer, and drug metabolism. Hepatology is published on behalf of the American Association for the Study of Liver Diseases (AASLD). For more information, please visit onlinelibrary.wiley/journal/10.1002/(ISSN)1527-3350 .